GlassScriptPhysician profile
Megan E Lubin
NPI 1972757722
$8,833.01
in general payments reported to CMS, 2019-2025
34 companies · $721 in 2025
The $721 reported for 2025 was more than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,538 · 2020: $128 · 2021: $2,104 · 2022: $1,397 · 2023: $1,019 · 2024: $1,925 · 2025: $721.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,668 · Travel and Lodging: $998.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,667.57 |
| Travel and Lodging | $997.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $1,515.15 | 2019-2025 | Inbone, Augment Injectable, Prostep Mica |
| Seapearl East, INC | $1,350.34 | 2021-2025 | |
| Organogenesis INC. | $1,330.45 | 2019-2025 | Puraply Wound Matrix, Via Matrix, Puraforce |
| Paragon 28, INC. | $1,186.18 | 2024 | Precision Mis Bunion, Bun-Yo-Matic |
| Globus Medical, INC. | $817.50 | 2019 | |
| Abbott Laboratories | $407.61 | 2020-2024 | Proclaim |
| Smith+Nephew, INC. | $362.59 | 2021-2025 | Grafix Pl, Stravix Pl |
| Zimmer Biomet Holdings, INC. | $312.86 | 2019-2022 | |
| Paratek Pharmaceuticals, INC. | $243.51 | 2022-2025 | Nuzyra |
| Integra Lifesciences Corporation | $187.47 | 2019-2022 | |
| Inari Medical, INC. | $139.58 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Nevro Corp. | $137.80 | 2019-2023 | Senza |
| Treace Medical Concepts, INC. | $103.99 | 2022-2025 | |
| Melinta Therapeutics, LLC | $101.75 | 2019 | |
| Convatec INC. | $82.94 | 2019-2024 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tactile Systems Technology INC | $66.50 | 2024-2025 | Flexitouch Plus, Nimbl, Entre Plus |
| Depuy Synthes Sales INC. | $55.55 | 2024 | Va-Lcp, Na, Vivigen Mis Delivery System |
| Sebela Pharmaceuticals INC. | $53.90 | 2019-2023 | Naftin |
| Royal Biologics, INC. | $53.38 | 2020 | |
| Bioventus LLC | $39.45 | 2019-2022 | |
| Medshape, INC. | $32.25 | 2023 | Dynanail Mini, Dynanail Helix, Washer, 15 Mm |
| Misonix INC | $27.70 | 2020-2021 | |
| Koya Medical, INC. | $26.53 | 2025 | Koya Medical, Dayspring |
| Heron Therapeutics, INC. | $25.45 | 2021 | |
| Reapplix INC. | $21.78 | 2024 | 3c Patch Kit - Box |
| Triad Life Sciences INC. | $21.52 | 2022 | |
| Kerecis Limited | $19.01 | 2022 | |
| Zimvie INC. | $18.34 | 2022 | |
| Mimedx Group, INC. | $17.08 | 2025 | |
| Wright Medical Technology, INC. | $16.91 | 2019 | |
| Linvatec Corporation | $16.90 | 2023 | Biobrace 23mm |
| Advanced Oxygen Therapy INC. | $14.96 | 2024 | Topical Oxygen Chamber For Extremities |
| Horizon Therapeutics Plc | $14.43 | 2022 | |
| Nabriva Therapeutics, Plc | $11.65 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Megan Lubin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.